Breast Health

COVID-19

Cervical Health 

Contraception

Curbside Consults

Dermatology

Drug Pipeline News

Endometriosis

Genetic Testing

Gynecologic Oncology

Gynecology

Fetal Imaging

Abnormal Obstetrical Ultrasound

Ultrasound

Women's Imaging

Breast Imaging

Women's Ultrasound

Imaging

Infertility

LARC

Legally Speaking

Life Transitions

Malpractice

Menopause

Mental Health

Noninvasive Prenatal Testing

Obstetrics

Opinion

Osteoporosis

Pediatrics

Practice Management

Pregnancy and Birth

Sexual Health

Sexually Transmitted Infections

Surgery

Technology

Urology

Uterine Fibroids

Vulvovaginal Disease

Well Woman

About

News

Media

Podcasts

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Videos

Conferences

Conference Coverage

Conference Listing

Publications

Contemporary OB/GYN® Journal

Digital Supplements

CME/CE

Resources

Physician Fact Sheets

Interactive Tools

Supplements and Featured Publications

Subscribe

Editorial Board

Partnerships

Elinzanetant, a non-hormonal drug, shows promising results in reducing hot flashes and night sweats, offering a new option for women seeking effective and safe treatment for vasomotor symptoms.

JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy

Articles

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Contemporary OB/GYN week in review: Elinzanetant, breast cancer, and more

Joshua Fitch is an editor for Contemporary Pediatrics. Previously, he worked at 21 WFMJ as a sports anchor and videographer, as well as a national content writer for Weigel Broadcasting Company. 

Research reveals that over a third of adolescents in pediatric emergency departments struggle with access to menstrual products, highlighting the need for improved public health measures.

Study reports period poverty in 1 in 3 adolescents

Despite an increase in mifepristone use to manage early pregnancy loss over time, rates remain low, preventing patients from receiving proven benefits.

Mifepristone use low for early pregnancy loss management

Advertise

Contact Us

Job Board

Terms of Use

Privacy Policy

Do Not Sell My Personal Information

Contemporary OB/GYN

Facebook

LinkedIn

RSS Feed

Spotlight

CMV: In the Know

RSV Roundtable

STIs

Supplement: Closing the Gap in Cervical Cancer Screening

Vaginismus: Managing a Misunderstood and Underdiagnosed Condition

Why vNOTES Make Sense for My Patients

1rem

Authors

Neural Plasticity in Dysmenorrheic Women: Menstrual Phase Hyperalgesia

A 27-year-old woman presents with an 18-month history of vulvar irritation. She is otherwise healthy except for episodes of depression. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole. She used oral steroids but developed knee pain. Tacrolimus has not helped. A biopsy revealed lichen simplex chronicus. Immunofluorescent studies were negative.

A 27-year-old woman presents with an 18-month history of vulvar irritation. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole without relief. What's your diagnosis?

Vulvar irritation in a 27-year-old woman

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

Elinzanetant long-term safety data with JoAnn Pinkerton, MD, FACOG, NCMP

At the 2024 Menopause Society meeting being held in Chicago, Illinois through September 14, 2024, JoAnn Pinkerton, MD, FACOG, NCMP, joined us to discuss phase 3 data of elinzanetant from the OASIS 3 trial.

The trial sought to evaluate the safety and efficacy of elinzanetant in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS).

"OASIS 3 is a clinical trial that built on OASIS 1 and 2, which were 26-week trials that were just published in 

," said Pinkerton, who is a professor of Obstetrics and Gynecology at The University of Virginia Health System in Charlottesville, Virginia.

"OASIS 3 was a longer clinical trial, 52 weeks, that took primarily women who are having bothersome menopausal symptoms of moderate to severe, and they observed them over a year for safety and efficacy. The primary endpoint was the reduction in hot flushes from baseline to 12 weeks, but then we really wanted to look at the safety and efficacy across 52 weeks," Pinkerton said. 

"The good news was that Oasis met its primary objective," she added. "Hot flashes were significantly reduced at 12 weeks in this population of women who were not as severe as those in OASIS 1 and 2—more like you would see in your clinical practice—significantly reduced compared to placebo at 12 weeks, and then maintained that efficacy throughout the 52 weeks.

Click here for more coverage from The Menopause Society Meeting.

Panay N, Joffe H, Maki P, et al. Efficacy and Long-term Safety of Elinzanetant for the Treatment of VMS Associated with Menopause: A Phase 3 Randomized Trial (OASIS 3). Abstract. Presented at: The Menopause Society 2024 Annual Meeting. September 10 - September 14, 2024. Chicago, Illinois.

Clinical

Saying "obstetrician-gynecologist" is a mouthful for most people, and it's probably the most abbreviated specialty in medicine, both spoken and written. However, there doesn't seem to be a consensus on how to pronounce OB-GYN. First, is it the two-syllable "O-B" or the monosyllabic "Ob"? Second, is it "gin" or "gyne" (like "Lyme")? I wonder if you have a preference. I know I do.

Almost nobody says "obstetrician-gynecologist" when speaking about these specialist physicians. But what's the "correct" way to pronounce OB/GYN?

Is It Ob-Gin or Ob-Gyne?

While often asymptomatic, uterine fibroids affect 70 to 80% of women in the U.S. by age 50 and can significantly impact their quality of life. AHN Women’s Institute has a highly specialized team that provides patients with options tailored for their condition and individual needs.

The team offers a full array of diagnostic and therapeutic procedures for uterine fibroids and treatment plans based on a patient’s symptoms. AHN’s fibroid specialists include gynecologists, urogynecologists, diagnostic radiologists, interventional radiologists, and nurse practitioners. They work collaboratively to streamline patients’ care, so they receive coordinated, comprehensive treatment.

“Early detection and intervention can considerably improve outcomes and minimize the potential complications associated with uterine fibroids,” said Noah Rindos, MD, an AHN minimally invasive gynecologist. “We encourage women to seek medical attention if they experience any concerning symptoms. Our goal is to deliver the safest, most effective treatments so patients can stay healthy.”

A common condition with diverse presentations

Uterine fibroids are the most common benign tumors in women of childbearing age. These growths run the gamut of presentations. Fibroids grow in and around the muscular wall of the uterus as a single tumor or as several. They can be as small as an apple seed or as big as a grapefruit, and they can grow or stay about the same size over time.

Fibroids can also manifest in a variety of ways, ranging from mild discomfort to severe pain and debilitating symptoms. Common symptoms include heavy menstrual bleeding, pelvic pain, and pressure on the bladder and rectum, which cause frequent urination or constipation. In some cases, fibroids can interfere with conception, impacting a patient’s reproductive goals.

For asymptomatic or minimally symptomatic patients, watching and waiting may be the most appropriate option because fibroids are rarely cancerous. This involves close monitoring and observation, with intervention only if symptoms worsen or become intolerable.

For patients experiencing mild to moderate symptoms, medical management can be effective. This may include hormonal therapy, including oral contraceptives to regulate menstrual cycles and reduce bleeding. Certain types of intrauterine devices (IUD) can also reduce heavy bleeding.

When medical management fails or symptoms are severe, patients may consider interventional procedures.

AHN Women’s Institute offers a range of minimally invasive and noninvasive procedures that result in fewer incisions and help patients recover faster. These approaches ease fibroid symptoms without affecting surrounding healthy tissue.

Uterine fibroid embolization (UFE) is a valuable treatment option for women with symptomatic fibroids who are not candidates for surgery or who prefer a less invasive approach. Doctors insert a catheter through an artery in the groin or wrist and guide it to the arteries supplying the fibroids with blood. The catheter releases small particles that cut off blood supply to the fibroids, so they shrink. This procedure also preserves the uterus.

“UFE has a high success rate in reducing fibroid size and alleviating symptoms. This is a great option for women who want to preserve their fertility and avoid major surgery,” Dr. Rindos said.

If nonsurgical treatments fail to resolve symptoms, the team may recommend surgery, including myomectomy and hysterectomy. AHN surgeons perform both as a minimally invasive procedure or an open surgery, depending on the patient’s case.

Committed to patient education and support

AHN’s comprehensive approach to uterine fibroids ensures patients receive the highest quality care, truly focused on their situation and needs. AHN offers support groups for women with uterine fibroids, providing a safe space to share experiences and connect with others. The team also has convenient scheduling options and multiple locations throughout the region, ensuring patients have easy access to care.

“Our team-based approach provides timely and effective relief,” Dr. Rindos said. “By combining advanced technology, expert physicians, and a commitment to patient education and support, we strive to empower women to manage their fibroids and live healthy, fulfilling lives.”

To refer a patient to AHN Women’s Institute, call 412-DOCTORS.

NOINDEX

NOFOLLOW

AHN Women’s Institute delivers optimal outcomes for patients with uterine fibroids

These are 3D ultrasound images of a 14-week fetus. What is your diagnosis?

occipital meningocele and umbilical hernia

DailyDx: 3D Images of a 14-week fetus

In a recent interview ObGyn.net conducted for 

 on comprehensive care and cancer screenings at well-woman visits, the topic of stethoscopes came up. Ilene S. Gewirtz, MD, the interviewee, mentioned that she still carries a stethoscope and listens to her patients' heart and lungs at well-woman visits. She also said that she believes she's in the minority regarding this practice. We want to know if she's right.

POLL: Many women consider their OB/GYN their primary care provider. But like your primary care counterpart, do you carry a stethoscope?

Priti Bajaj

Articles

Latest Updated Articles